The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood
Abstract
PURPOSE: To quantify the long-term risk of second primary cancers (SCs) in patients diagnosed with Hodgkin’s disease (HD) during adolescence or young adulthood. PATIENTS AND METHODS: The risk of SCs was assessed in 1,253 patients diagnosed with HD before the age of 40 years and treated in two Dutch cancer centers between 1966 and 1986. The median follow-up duration was 14.1 years. RESULTS: In all, 137 patients developed SCs, compared with 19.4 cases expected on the basis of incidence rates in the general population (relative risk [RR] = 7.0; 95% confidence interval, 5.9 to 8.3). The 25-year actuarial risk of SC overall was 27.7%. The RR of solid tumors increased greatly with younger age at the first treatment of HD, not only for breast cancer but also for all other solid tumors, with RRs of 4.9, 6.9, and 12.7 for patients first treated at ages 31 to 39 years, 21 to 30 years, and ≤ 20 years, respectively. Among patients first treated at the age of 20 years or younger, the RR of developing a solid tumor before the age of 40 years was significantly greater than the RR of solid tumor development at ages 40 to 49 years (RR = 27.9 v RR = 4.2; P = .0001). Patients who received salvage chemotherapy had significantly greater risk of solid cancers other than breast cancer than did patients whose treatment was restricted to initial radiotherapy or initial combined-modality treatment (RR = 9.4 and 4.7, respectively; P = .004). CONCLUSION: After more than 20 years of follow-up, the risk of solid tumors is still much greater in survivors of HD than in the population at large. Reassuringly, the greatly increased risk of solid tumors in patients who were young (≤ 20 years of age) at the first treatment seems to decrease as these patients grow older. Our data suggest that chemotherapy may increase the risk of solid tumors from radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Huerta, G. T., & Villasana, J. E. M. (1988) · PubMed · Cited by 804
Risk of Second Cancers after Treatment for Hodgkin's Disease
Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180203 · Cited by 718
Thyroid Diseases after Treatment of Hodgkin's Disease
Hancock, S. L., Cox, R. S., & McDougall, I. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108293250902 · Cited by 579
Breast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Cited by
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Self-citationNeglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., & Robison, L. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.618 · Cited by 741
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van’t Veer, M. B., Bartelink, H., & van Leeuwen, F. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.131 · Cited by 716
Self-citationBreast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., et al. (2003) · JAMA · doi:10.1001/jama.290.4.465 · Cited by 666
Self-citationSecond Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Self-citationDores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.038 · Cited by 565
Self-citationCardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
Self-citationvan Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P. M., Krol, A. D. G., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4444 · Cited by 464
Self-citationEngert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., Boissevain, F., de Wit, M., Mezger, J., Dühmke, E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.023 · Cited by 460
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W. J., Ribot, J. G., Hoekstra, H. J., Ouwens, G. M., Aleman, B. M. P., & van Leeuwen, F. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5296 · Cited by 453
Self-citationNg, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., & Mauch, P. M. (2002) · Blood · doi:10.1182/blood-2002-02-0634 · Cited by 433
Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C. F., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji290 · Cited by 425
Self-citationvan Leeuwen, F. E., Klokman, W. J., Stovall, M., Dahler, E. C., van't Veer, M. B., Noordijk, E. M., Crommelin, M. A., Aleman, B. M. P., Broeks, A., Gospodarowicz, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.971 · Cited by 402
Self-citationEpidemiology of Neuroendocrine Tumours
Taal, B. G., & Visser, O. (2004) · Neuroendocrinology · doi:10.1159/000080731 · Cited by 381
Gao, X., Fisher, S. G., & Emami, B. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00203-7 · Cited by 372
Castellino, S. M., Geiger, A. M., Mertens, A. C., Leisenring, W. M., Tooze, J. A., Goodman, P., Stovall, M., Robison, L. L., & Hudson, M. M. (2011) · Blood · doi:10.1182/blood-2010-04-278796 · Cited by 367
Radiation and breast cancer: a review of current evidence
Ronckers, C. M., Erdmann, C. A., & Land, C. E. (2004) · Breast Cancer Research · doi:10.1186/bcr970 · Cited by 366
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
Hodgson, D. C., Gilbert, E. S., Dores, G. M., Schonfeld, S. J., Lynch, C. F., Storm, H., Hall, P., Langmark, F., Pukkala, E., Andersson, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0936 · Cited by 351
Incidence of Female Breast Cancer among Atomic Bomb Survivors, Hiroshima and Nagasaki, 1950–1990
Land, C. E., Tokunaga, M., Koyama, K., Soda, M., Preston, D. L., Nishimori, I., & Tokuoka, S. (2003) · Radiation Research · doi:10.1667/rr3082 · Cited by 347
Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence
Metayer, C., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., Joensuu, T., van Leeuwen, F. E., van’t Veer, M. B., Curtis, R. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2435 · Cited by 340
Self-citationRisk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma
Cutter, D. J., Schaapveld, M., Darby, S. C., Hauptmann, M., van Nimwegen, F. A., Krol, A. D. G., Janus, C. P. M., van Leeuwen, F. E., & Aleman, B. M. P. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv008 · Cited by 310
Self-citationGordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4803 · Cited by 308
Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V., & Engert, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.138 · Cited by 296
Furth, C., Amthauer, H., Hautzel, H., Steffen, I. G., Ruf, J., Schiefer, J., Schönberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq557 · Cited by 43
Metadata
- Authors
- van Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., & Aleman, B. M. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-02-01
- Volume
- 18
- Issue
- 3
- Pages
- 487-487
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2243890309
- Cited by
- 436
- References
- 30
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.